IP Library › Granted Patent US 11,964,072
Granted Patent B2
US 11,964,072 · App. 16/337,350 · Granted Apr 23, 2024

Soft tissue adhesive composition of α-TCP and phosphorylated amino acid

Inventors: Philip Procter (Divonne les Bains, FR); Håkan Engqvist (Uppsala, SE); Michael Pujari-Palmer (Uppsala, SE); Gerard Insley (Limerick, IE)
Assignee: BIOMIMETIC INNOVATIONS LIMITED
A61L24/0031A61L24/0084A61L24/02A61L27/54A61L2430/34
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,964,072
App. No.
16/337,350
Granted
Apr 23, 2024
Kind
B2
Abstract

The present invention relates to a soft tissue adhesive comprising an aqueous composition comprising α-TCP and a phosphorylated amino acid. The composition has improved mechanical strength and is easily applied to the tissue.

Claims (18)

1. A method of adhering a first soft tissue to a second soft tissue using a tissue adhesive comprising an aqueous solution, α-TCP, a phosphorylated amino acid, and a silicate compound, comprising:

a. applying the tissue adhesive to the first soft tissue or to the second soft tissue and optionally leave it for a suitable period of time;

b. bringing the first tissue and the second tissue into contact with each other;

c. optionally applying a pressure on the first and second tissue for a suitable period of time; and

d. letting the tissue adhesive cure;

wherein the phosphorylated amino acid content of the tissue adhesive is 15-45 wt % of the solid content, wherein the amount of α-TCP is 50 wt % or higher of the solid content and wherein the silicate compound is a mixture of di- and tricalcium silicate.

2. The method according to claim 1 wherein at least one of the first and the second soft tissue is selected from tendon, ligament, fascia, skin, fibrous tissue, muscle, fat, nerve or blood vessel.

3. The method according to claim 1 wherein the steps are performed in vitro.

4. The method according to claim 1 wherein at least 95 wt % of the composition comprises an aqueous solution, α-TCP, and a phosphorylated amino acid.

5. The method according to claim 1 wherein the amount of phosphorylated amino acid is 20-45 wt %.

6. The method according to claim 1 wherein the amount of phosphorylated amino acid is 15-37 wt %.

7. The method according to claim 1 wherein the amount of phosphorylated amino acid is 15-30 wt %.

8. The method according to claim 1 wherein at least 98 wt % of the composition comprises an aqueous solution, α-TCP, and a phosphorylated amino acid.

9. The method according to claim 1 wherein at least 98 wt % of the composition comprises an aqueous solution, α-TCP and wherein the amount of phosphorylated amino acid is 15-35%.

10. The method according to claim 1 wherein the phosphorylated amino acid is phosphorylated serine.

11. The method according to claim 1 wherein the aqueous solution is water.

12. The method according to claim 1 wherein the composition further comprises a hydrogel.

13. The method according to claim 1 wherein the first or second soft tissue may be selected from the group consisting of tendon, ligament, cartilage, fascia, skin, fibrous tissue, muscle, fat, nerve, blood vessel, liver, stomach, hair, eye lashes, intestines, bladder, brain, eyes, uterus, lungs, esophagus, heart, lung, kidney, spleen and glands.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 16, 2021
From: GPBIO LIMITED
To: BIOMIMETIC INNOVATIONS LIMITED
Reel/Frame 056561/0063 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 11, 2019
From: PROCTER, PHILIP; ENGQVIST, HAKAN; PUJARI-PALMER, MICHAEL; INSLEY, GERARD
To: GPBIO LTD.
Reel/Frame 049728/0985 →
Priority Claims (2)
SE 1651271-7 · Sep 27, 2016 · national
SE 1651727-8 · Dec 22, 2016 · national
Continuity (1)
Related Publication 20200030483A1 · Jan 30, 2020